An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis and an increased risk of transformation. Few effective therapies are available for lower risk MDS patients, especially after the failure of hypomethylating agents. MDS progenitor cells are dependent on the nuclear factor‐κB (NF‐κB) for survival, which makes it an attractive therapeutic target. As a proteosomal inhibitor, bortezomib is thought to have inhibitory activity against NF‐κB. We designed a proof‐of‐principle study of subcutaneous (SC) bortezomib in lower risk MDS patients with evidence of NF‐κB activation in their bone marrow. Fifteen patients were treated, their median age was 71 (range 56–87), 33% were low and 67% int‐1 by IPSS, median number of prior therapies was 2, all patients were transfusion dependent. Baseline median pp65 percentage was 31% and 11 patients had evidence of ring sideroblasts (RS). SC bortezomib was safe, well tolerated with no excess toxicity. Three patients out of the 15 (20%) had evidence of response with hematologic improvement (HI‐E). Bortezomib caused a decrease in pp65 levels in 7 out of 13 evaluable patients (54%, P = .025). Of interest, unexpectedly, we observed a significant decrease in RS in 7 out of 10 (70%) evaluable patients during treatment. In conclusion, this study suggests that NF‐κB activation, measured by pp65 levels, may be a useful biomarker in MDS. Bortezomib is safe in this patient population but has modest clinical activity. The role of the proteasome in the genesis of RS needs further study.

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  F. Ravandi,et al.  Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. , 2016, American journal of clinical pathology.

[3]  R. Goswami,et al.  Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms , 2016, Modern Pathology.

[4]  F. Stingo,et al.  Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS , 2016, Oncotarget.

[5]  J. Issa,et al.  Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. , 2016, Journal of the National Cancer Institute.

[6]  G. Garcia-Manero,et al.  Myelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and management , 2015, American journal of hematology.

[7]  H. Kantarjian,et al.  Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium , 2015, Cancer.

[8]  S. Colla,et al.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes , 2015, Leukemia.

[9]  Taro Kawai,et al.  Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..

[10]  M. Grever,et al.  Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia , 2014, Leukemia & lymphoma.

[11]  P. Campbell,et al.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes , 2014, Leukemia.

[12]  H. Kantarjian,et al.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.

[13]  D. Neuberg,et al.  Toll-like receptor alterations in myelodysplastic syndrome , 2013, Leukemia.

[14]  R. Chen,et al.  Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes , 2013, PloS one.

[15]  A. Baldwin,et al.  Deletion of the NF-κB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. , 2013, Blood.

[16]  J. Testa,et al.  NF-κB Inhibition by Bortezomib Permits IFN-γ–Activated RIP1 Kinase–Dependent Necrosis in Renal Cell Carcinoma , 2013, Molecular Cancer Therapeutics.

[17]  C. Bloomfield,et al.  Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  I. Weissman,et al.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes , 2013, Proceedings of the National Academy of Sciences.

[19]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[20]  A. Stamatoullas,et al.  Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM , 2012, British journal of haematology.

[21]  H. Kantarjian,et al.  Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. , 2012, The Journal of molecular diagnostics : JMD.

[22]  M. Karin,et al.  NF‐κB and the link between inflammation and cancer , 2012, Immunological reviews.

[23]  N. Perkins,et al.  The diverse and complex roles of NF-κB subunits in cancer , 2012, Nature Reviews Cancer.

[24]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[25]  B. Aggarwal,et al.  NF-κB addiction and its role in cancer: ‘one size does not fit all’ , 2011, Oncogene.

[26]  Z. Estrov,et al.  STAT-3 Activates NF-κB in Chronic Lymphocytic Leukemia Cells , 2011, Molecular Cancer Research.

[27]  Rajyalakshmi Luthra,et al.  Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. , 2011, American journal of clinical pathology.

[28]  Hao Wu,et al.  Structural studies of NF-κB signaling , 2011, Cell Research.

[29]  Lin-Feng Chen,et al.  Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. , 2010, Cellular signalling.

[30]  Matthias W. Hentze,et al.  Two to Tango: Regulation of Mammalian Iron Metabolism , 2010, Cell.

[31]  J. Byrd,et al.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide , 2009, Proceedings of the National Academy of Sciences.

[32]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[33]  A. Protopopov,et al.  Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. , 2009, Blood.

[34]  Alexander A. Shishkin,et al.  Targeting transcription factor NFκB: comparative analysis of proteasome and IKK inhibitors , 2009, Cell cycle.

[35]  P. Moreau,et al.  Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma , 2008, Haematologica.

[36]  D. McConkey,et al.  Mechanisms of proteasome inhibitor action and resistance in cancer. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  M. Caligiuri,et al.  Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. , 2008, Blood.

[38]  Ø. Bruserud,et al.  The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells , 2007, British journal of haematology.

[39]  A. Biederbick,et al.  Iron-Dependent Degradation of Apo-IRP1 by the Ubiquitin-Proteasome Pathway , 2007, Molecular and Cellular Biology.

[40]  G. Kroemer,et al.  NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. , 2007, Oncogene.

[41]  T. Rouault.  The role of iron regulatory proteins in mammalian iron homeostasis and disease , 2006, Nature chemical biology.

[42]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[43]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[44]  J. Schmid,et al.  BMS-345541 Targets Inhibitor of κB Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor κB and Mitochondria Pathways , 2006, Clinical Cancer Research.

[45]  G. Kroemer,et al.  NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. , 2006, Blood.

[46]  J. Schmid,et al.  BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  É. Álvarez,et al.  Inhibition of NF-κB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines , 2005 .

[48]  G. Kroemer,et al.  NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome , 2005 .

[49]  D. Esseltine,et al.  Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. , 2005, Blood.

[50]  E. Estey,et al.  Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias , 2004, Clinical Cancer Research.

[51]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[52]  Terry L. Smith,et al.  Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. , 2004, Human pathology.

[53]  A. Israël.  Signal transduction: A regulator branches out , 2003, Nature.

[54]  A. Strasser,et al.  B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. , 2002, Molecular cell.

[55]  D. Howard,et al.  Preferential induction of apoptosis for primary human leukemic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[57]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[58]  F. Prósper,et al.  Nuclear factor k B is activated in myelodysplastic bone marrow cells. , 2002, Haematologica.

[59]  D. Howard,et al.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. , 2001, Blood.

[60]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[61]  I. Bernstein,et al.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. , 2001, Blood.

[62]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[63]  M. Kitagawa,et al.  Ubiquitin-dependent degradation of I_B_ is mediated by a′ ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. , 1999 .

[64]  M. Kitagawa,et al.  Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[65]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[66]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.